Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004

Active Not RecruitingPhase 3

Sponsor: Hoffmann-La Roche

Conditions: Multiple Sclerosis

Interventions: Ocrelizumab

Countries: United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion criteria

* Prior eligibility for and previous participation in 1 of the Roche-sponsored Parent Studies WA21092, WA21093, or WA25046 with the participant either receiving ocrelizumab as an investigational medicinal product (IMP) or being in safety follow-up after treatment discontinuation
* For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate acceptable contraception during the treatment period and for at least 6 months or longer if the local label is more stringent after the final dose of ocrelizumab, as applicable in the ocrelizumab package leaflet

Exclusion criteria

* Concurrent participation in any clinical trial (other than the Parent study)
* Unable or unwilling to comply with the requirements of the protocol
Locations (236)
  • Phoenix, Arizona, United States
  • Phoenix, Arizona, United States
  • Laguna Hills, California, United States
  • Palo Alto, California, United States
  • San Francisco, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Fort Collins, Colorado, United States
  • Maitland, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Vero Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Northbrook, Illinois, United States
  • Indianapolis, Indiana, United States
  • Kansas City, Kansas, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Detroit, Michigan, United States
  • Farmington Hills, Michigan, United States
  • Golden Valley, Minnesota, United States
  • Minneapolis, Minnesota, United States
  • St Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Newark, New Jersey, United States
  • Teaneck, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Patchogue, New York, United States
  • + 206 more on CT.gov